Boehringer Ingelheim Reports Positive Results For Recover Study

Boehringer Ingelheim has reported results from the Recover study investigating Dabigatran Etexilate (150 mg BID), a direct thrombin inhibitor (DTI), compared to dose-adjusted Warfarin in patients with acute VTE.

Dabigatran Etexilate met the primary outcome of the trial, six month incidence of recurrent symptomatic VTE and related deaths, and was non-inferior to dose-adjusted warfarin in patients with acute VTE (2.4% versus 2.1%). There were 37% fewer patients treated with Dabigatran Etexilate who experienced major or clinically relevant non-major bleeds versus patients treated with Warfarin.

The percentage of patients experiencing major bleeds was 1.6 in the Dabigatran Etexilate group and 1.9 in the Warfarin group. The number of patients with any bleeding was 29% lower in the group treated with Dabigatran Etexilate.

The study helps in treating acute, clinically documented VTE with a parenteral heparin preparation for at least five days followed by oral anticoagulation with a vitamin K antagonist, such as Warfarin.

Janet Schnee, clinical program director of Boehringer Ingelheim, said: “The standard of care for patients with VTE is anticoagulation. It is encouraging to see that the results of this study suggest that Dabigatran Etexilate has the potential to be an alternative treatment for VTE.”

Wa’el Hashad, vice president of cardiovascular and metabolics marketing at Boehringer Ingelheim, said: “The Recover study results suggest Dabigatran Etexilate could potentially provide a convenient treatment option for patients with VTE.”